NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zelira Therapeutics Limited (OTCQB: ZLDAF)

 
ZLDAF Technical Analysis
1
As on 27th Aug 2024 ZLDAF STOCK Price closed @ 0.49 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZLDAFSTOCK Price

Open 0.49 Change Price %
High 0.49 1 Day N/A N/A
Low 0.49 1 Week 0.00 0.00
Close 0.49 1 Month 0.00 0.00
Volume N/A 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
OTCQB USA Most Active Stocks
BMIX 0.01 %
NWBO 0.33 %
VPLM 0.01 %
ALPP 3.56 0.00%
ALPP 3.56 0.00%
VKIN 0.23 0.00%
ELTP 0.25 %
RDGL 0.13 %
SRNA 2.78 14.88%
MMTIF 0.02 %
 
OTCQB USA Top Gainers Stocks
EMMLF 0.89 8800.00%
EWLUD 0.45 275.00%
HCAND 0.02 100.00%
TRYPF 0.06 50.00%
TUMIF 0.09 50.00%
EXDI 0.82 38.98%
NVMDF 0.27 35.00%
NVMDF 0.27 35.00%
GYRRF 0.24 33.33%
DSMTF 0.04 33.33%
 
OTCQB USA Top Losers Stocks
MCURF 0.03 -40.00%
NOCSF 0.13 -23.53%
GENH 0.14 -22.22%
EMPR 19.46 -20.73%
EMPR 19.46 -20.73%
CURR 0.08 -20.00%
IFNY 0.04 -20.00%
NIKLF 0.05 -16.67%
UBMRD 0.56 -15.15%
NPDCF 0.06 -14.29%
 
 
ZLDAF
Daily Charts
ZLDAF
Intraday Charts
Whats New @
Bazaartrend
ZLDAF
Free Analysis
 
ZLDAF Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
ZLDAF Forecast September 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
ZLDAF Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
ZLDAF Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
ZLDAF Other Details
Segment EQ
Market Capital 33018180.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZLDAF Address
ZLDAF
 
ZLDAF Latest News
 
Your Comments and Response on Zelira Therapeutics Limited
 
ZLDAF Business Profile
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; the Children's Hospital of Philadelphia (CHOP) on opioid reduction study; HAPA Pharm BV; and Ethicann. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was founded in 2003 and is headquartered in Perth, Australia. Address: 101 St Georges Terrace, Perth, WA, Australia, 6000
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service